EA202192860A1 - Сиалилированные гликопротеины - Google Patents
Сиалилированные гликопротеиныInfo
- Publication number
- EA202192860A1 EA202192860A1 EA202192860A EA202192860A EA202192860A1 EA 202192860 A1 EA202192860 A1 EA 202192860A1 EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A1 EA202192860 A1 EA 202192860A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mechanical stress
- hsigg
- resistant
- sialylated glycoproteins
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Описаны фармацевтические препараты, содержащие гиперсиалилированные иммуноглобулины (hsIgG). Препараты устойчивы к механическому воздействию. Описанные в данном документе фармацевтические композиции обеспечивают фармацевтически приемлемые композиции hsIgG, которые устойчивы к механическому воздействию (например, если состав подвергается механическому воздействию, такому как встряхивание, например, во время транспортировки, при этом не происходит образования значительного количества невидимых частиц) и которые, таким образом, можно транспортировать и обрабатывать в жидкой форме.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962836016P | 2019-04-18 | 2019-04-18 | |
PCT/US2020/028863 WO2020215021A1 (en) | 2019-04-18 | 2020-04-17 | Sialylated glycoproteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192860A1 true EA202192860A1 (ru) | 2021-12-23 |
Family
ID=72837963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192860A EA202192860A1 (ru) | 2019-04-18 | 2020-04-17 | Сиалилированные гликопротеины |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220211849A1 (ru) |
EP (1) | EP3955962A4 (ru) |
JP (1) | JP2022529168A (ru) |
KR (1) | KR20220002963A (ru) |
CN (1) | CN113795275A (ru) |
AU (1) | AU2020259492A1 (ru) |
BR (1) | BR112021020509A8 (ru) |
CA (1) | CA3137101A1 (ru) |
CL (1) | CL2021002668A1 (ru) |
CO (1) | CO2021013926A2 (ru) |
CR (1) | CR20210521A (ru) |
EA (1) | EA202192860A1 (ru) |
EC (1) | ECSP21078309A (ru) |
IL (1) | IL287306A (ru) |
JO (1) | JOP20210281A1 (ru) |
MX (1) | MX2021012710A (ru) |
PE (1) | PE20220383A1 (ru) |
SG (1) | SG11202110942SA (ru) |
WO (1) | WO2020215021A1 (ru) |
ZA (1) | ZA202109184B (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
WO2022109327A1 (en) | 2020-11-20 | 2022-05-27 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US11735303B2 (en) * | 2021-06-22 | 2023-08-22 | David Haase | Apparatus and method for determining a composition of a replacement therapy treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4662557B2 (ja) * | 2003-06-09 | 2011-03-30 | レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー | 酸化還元反応による血漿タンパク質の結合特異性の改変方法 |
EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
NZ599176A (en) * | 2005-08-03 | 2014-04-30 | Immunogen Inc | Immunoconjugate formulations |
SG176256A1 (en) * | 2009-05-27 | 2012-01-30 | Baxter Int | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
FR2961107B1 (fr) * | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines stabilisee |
US20150252108A1 (en) * | 2012-09-26 | 2015-09-10 | Momenta Pharmaceuticals, Inc. | Glycoprotein preparations |
ES2802274T3 (es) * | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
WO2014191240A1 (en) * | 2013-05-29 | 2014-12-04 | F. Hoffmann-La Roche Ag | Quantitative control of sialylation |
CN110167531A (zh) * | 2017-01-11 | 2019-08-23 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
-
2020
- 2020-04-17 CR CR20210521A patent/CR20210521A/es unknown
- 2020-04-17 CN CN202080029642.8A patent/CN113795275A/zh active Pending
- 2020-04-17 JO JOP/2021/0281A patent/JOP20210281A1/ar unknown
- 2020-04-17 SG SG11202110942SA patent/SG11202110942SA/en unknown
- 2020-04-17 CA CA3137101A patent/CA3137101A1/en active Pending
- 2020-04-17 BR BR112021020509A patent/BR112021020509A8/pt unknown
- 2020-04-17 WO PCT/US2020/028863 patent/WO2020215021A1/en active Application Filing
- 2020-04-17 EP EP20792022.4A patent/EP3955962A4/en active Pending
- 2020-04-17 KR KR1020217037216A patent/KR20220002963A/ko unknown
- 2020-04-17 MX MX2021012710A patent/MX2021012710A/es unknown
- 2020-04-17 JP JP2021561870A patent/JP2022529168A/ja active Pending
- 2020-04-17 US US17/602,156 patent/US20220211849A1/en active Pending
- 2020-04-17 PE PE2021001732A patent/PE20220383A1/es unknown
- 2020-04-17 EA EA202192860A patent/EA202192860A1/ru unknown
- 2020-04-17 AU AU2020259492A patent/AU2020259492A1/en active Pending
-
2021
- 2021-10-12 CL CL2021002668A patent/CL2021002668A1/es unknown
- 2021-10-15 CO CONC2021/0013926A patent/CO2021013926A2/es unknown
- 2021-10-17 IL IL287306A patent/IL287306A/en unknown
- 2021-10-22 EC ECSENADI202178309A patent/ECSP21078309A/es unknown
- 2021-11-17 ZA ZA2021/09184A patent/ZA202109184B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202109184B (en) | 2023-04-26 |
CL2021002668A1 (es) | 2022-05-27 |
US20220211849A1 (en) | 2022-07-07 |
KR20220002963A (ko) | 2022-01-07 |
AU2020259492A1 (en) | 2021-11-11 |
JP2022529168A (ja) | 2022-06-17 |
WO2020215021A1 (en) | 2020-10-22 |
JOP20210281A1 (ar) | 2023-01-30 |
BR112021020509A8 (pt) | 2023-01-10 |
SG11202110942SA (en) | 2021-11-29 |
CN113795275A (zh) | 2021-12-14 |
CO2021013926A2 (es) | 2021-10-29 |
MX2021012710A (es) | 2021-11-12 |
IL287306A (en) | 2021-12-01 |
EP3955962A4 (en) | 2022-12-14 |
ECSP21078309A (es) | 2021-11-30 |
BR112021020509A2 (pt) | 2022-03-15 |
CR20210521A (es) | 2022-04-01 |
PE20220383A1 (es) | 2022-03-18 |
CA3137101A1 (en) | 2020-10-22 |
EP3955962A1 (en) | 2022-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202192860A1 (ru) | Сиалилированные гликопротеины | |
EA201992377A1 (ru) | Стабильная композиция антитела | |
MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
MX2020007697A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos. | |
AR108317A1 (es) | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
EP4223774A3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
EA201990831A1 (ru) | Смесительная система для получения косметического продукта и косметическая капсула | |
MX2023013577A (es) | Composiciones de bismuto-tiol y metodos de uso. | |
CL2017003208A1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
EA201892446A1 (ru) | Фармацевтическая композиция | |
MX2022001721A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos. | |
WO2015058173A8 (en) | Stable solid units and methods of making the same | |
PH12021550226A1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
SA521430229B1 (ar) | Il-33 صيغ ثابتة تحتوي على أجسام مضادة لـ | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
MX2022006130A (es) | Composiciones inyectables de ácido ursodeoxicólico. | |
PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
SG10201807034XA (en) | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease | |
MX2022005317A (es) | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. | |
EA202090568A1 (ru) | Составы копанлисиба | |
JOP20220097A1 (ar) | كريزانليزوماب يحتوي على صياغات اجسام مضادة | |
EA202191254A1 (ru) | Олигосахаридные препараты и композиции | |
DOP2024000066A (es) | Dendrones peptídicos y métodos de uso de los mismos |